The two companies will perform joint research funded by Centocor applying the unique properties of nanobodies. The companies will work jointly on novel approaches for administration and delivery of nanobody-based therapeutics.
Nanobodies are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs. Nanobodies have the affinity and selectivity of conventional antibodies yet are only a fraction of their size.
“Through this partnership we create a unique opportunity for Ablynx, by combining our own know-how on the nanobody platform with the world-class expertise of Centocor, who are considered as the benchmark in therapeutic antibody development,” said Dr Mark Vaeck, CEO of Ablynx.
The financial terms of the collaboration were not disclosed.